Pharmacokinetic data of the metabolite PA in the rat blood and bile
For PZA alone, a dose of 50 mg/kg i.v. PZA was administered. For the PZA + long-term silibinin exposure group, 100 mg/kg p.o. silibinin was given for three consecutive days; on the fourth day 50 mg/kg i.v. PZA was administered. For the PZA + concomitant short-term silibinin exposure group, 30 mg/kg i.v. silibinin was coadministered with 50 mg/kg i.v. PZA. Six individual rats were used in each group. Data are expressed as mean ± S.E.M. (n = 6).
PZA Alone Group | PZA + Long-Term Silibinin Exposure Group | PZA + Concomitant Short-Term Silibinin Exposure Group | |
|---|---|---|---|
| Blood | |||
| AUC (min/μg/ml) | 212 ± 22 | 809 ± 69a | 568 ± 23a |
| Bile | |||
| AUC (min/μg/ml) | 527 ± 28 | 649 ± 29 | 407 ± 76 |
| AUCbile/AUCblood | 2.67 ± 0.63 | 0.81 ± 0.02a | 0.80 ± 0.07a |
↵ a P < 0.05 significantly different from the PZA alone group.